UCBJY News and Press, UCB S.A. ADR From 02/27/21

UCB SA (UCBJF) Q4 2020 Results Conference Call February 25, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl...

The following slide deck was published by UCB SA in conjunction with their 2020 Q4 earnings call. For further details see: UCB SA 2020 Q4 - Results - Earnings Call Presentation

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future · Revenue increased to € 5.3 billion (+9%, +8% CER[1]) net sales to € 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was € 1.4 billion (+1%, -4%...

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI ...

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy - Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable - UCB invested €25 million ($29...

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020 ATLANTA , Dec. 4, 2020 /PRNewswire/ -- UCB today announced that 15 scientific posters will be presented at the upcoming Ameri...

Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics PR Newswire SANTA FE, N.M., Dec. 1, 2020 SANTA FE, N.M. , Dec. 1, 2020 /PRNewswire/ -- Specifica, a company revolutionizing antibody discovery, today announced that i...

World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19 - A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with C...

UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy -- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generali...

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms - Acquisition of Handl Therapeutics BV augments UCB's existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid tech...